News

The Pharma Letter4h
Lilly’s once-weekly insulin efsitora alfa hits Phase III goals
US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...
New once-a-week insulin could change how we treat type 2 diabetes
An experimental once-weekly insulin known as efsitora has shown comparable effectiveness to daily insulin regimens in ...